Format

Send to

Choose Destination
Cancer Biomark. 2017 Dec 12;21(1):41-53. doi: 10.3233/CBM-170209.

Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment.

Author information

1
Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
2
Department of Hematology, ASST Spedali Civili, Brescia, Italy.
3
Department of Information Engineering, University of Padova, Padova, Italy.
4
Internal Medicine-Haematology, Desio Hospital, Desio, Italy.
5
Division of Hematology, Department of Internal Medicine, Valduce Hospital, Como, Italy.
6
Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
7
Hematology Division, San Gerardo Hospital, Monza, Italy.
8
Oncohematology Division, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, Milano, Italy.
9
Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy.
10
Division of Hematology - Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
11
ASST Valle Olona Ospedale di Circolo, Busto Arsizio, Italy.
12
Division of Hematology, Hospital of Cremona, Cremona, Italy.
13
ASST Valle Olona Sant'Antonio Abate, Gallarate, Italy.
14
ASST Lecco, Lecco, Italy.
15
Hematology and Transfusion Medicine, Sacco Hospital, Milano, Italy.
16
Pathology Department, Cytogenetics, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.
17
Executive Committee, Rete Ematologia Lombarda, Italy.

Abstract

BACKGROUND:

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder with heterogeneous biological and clinical features. The biomolecular mechanisms of CML response to tyrosine-kinase inhibitors are not fully defined.

OBJECTIVE:

We undertook a gene expression profiling (GEP) study of selected bone marrow (BM) CD34+/lin- cells of chronic-phase CML patients at diagnosis and after 12 months of TKI nilotinib to investigate molecular signatures characterizing both conditions.

PMID:
29036785
DOI:
10.3233/CBM-170209
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center